Enzo Biochem Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Enzo Biochem.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Healthcare croissance des bénéfices	20.9%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Enzo Biochem n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

NYSE:ENZ - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
7/31/2024	32	-10	-27	-26	N/A
4/30/2024	33	-18	-43	-42	N/A
1/31/2024	33	-23	-46	-44	N/A
10/31/2023	32	-25	-44	-42	N/A
7/31/2023	31	-25	-40	-37	N/A
4/30/2023	-32	-27	-32	-29	N/A
1/31/2023	-13	-24	-28	-25	N/A
10/31/2022	13	-23	-22	-19	N/A
7/31/2022	33	-20	-20	-17	N/A
4/30/2022	112	-7	-12	-7	N/A
1/31/2022	118	0	-10	-4	N/A
10/31/2021	116	5	-9	-4	N/A
7/31/2021	118	8	-4	0	N/A
4/30/2021	112	1	-9	-5	N/A
1/31/2021	97	-11	-14	-11	N/A
10/31/2020	84	-21	-19	-16	N/A
7/31/2020	76	-29	-19	-17	N/A
4/30/2020	77	-31	-17	-15	N/A
1/31/2020	80	2	10	12	N/A
10/31/2019	80	1	1	9	N/A
7/31/2019	81	2	-3	5	N/A
4/30/2019	83	2	-2	6	N/A
1/31/2019	89	-23	-26	-18	N/A
10/31/2018	95	-16	-13	-12	N/A
7/31/2018	101	-10	-5	-3	N/A
4/30/2018	106	-4	N/A	1	N/A
1/31/2018	108	-2	N/A	3	N/A
10/31/2017	108	-2	N/A	3	N/A
7/31/2017	105	-3	N/A	0	N/A
4/30/2017	106	34	N/A	34	N/A
1/31/2017	106	31	N/A	30	N/A
10/31/2016	104	39	N/A	40	N/A
7/31/2016	103	45	N/A	53	N/A
4/30/2016	102	18	N/A	21	N/A
1/31/2016	99	17	N/A	23	N/A
10/31/2015	98	6	N/A	12	N/A
7/31/2015	98	-2	N/A	-4	N/A
4/30/2015	97	-14	N/A	-7	N/A
1/31/2015	97	-11	N/A	-3	N/A
10/31/2014	97	-11	N/A	-1	N/A
7/31/2014	96	-10	N/A	-2	N/A
4/30/2014	94	-10	N/A	-4	N/A
1/31/2014	93	-15	N/A	-10	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de ENZ est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de ENZ devraient croître plus rapidement que le marché US

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de ENZ devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de ENZ devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de ENZ devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ENZ devrait être élevé dans 3 ans

Enzo Biochem Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027

Recent updates

Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?

New minor risk - Dividend sustainability

Full year 2024 earnings released: US$0.19 loss per share (vs US$0.51 loss in FY 2023)

Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024

High number of new and inexperienced directors

Enzo Biochem: Is This Time Finally Different?

Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.059 loss in 2Q 2023)

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

Enzo Biochem, Inc. announced delayed annual 10-K filing

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022

CEO & Director recently bought US$197k worth of stock

Insider recently bought US$5.0m worth of stock

High number of new and inexperienced directors

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023

Enzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022

Enzo Biochem appoints Patricia Eckert as interim CFO

Full year 2022 earnings released

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2

Enzo Biochem, Inc. to Launch Monkeypox Testing Services This Week

Enzo Biochem, Inc. Announces Executive Changes

Independent Director recently bought US$264k worth of stock

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Independent Director recently bought US$276k worth of stock

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)

Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

High number of new and inexperienced directors

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management Positions

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022

High number of new and inexperienced directors

Less than half of directors are independent

Insider recently bought US$2.5m worth of stock

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$1.5m worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)

Insider recently bought US$2.5m worth of stock

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Enzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value Index

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)

Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a Director

Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)

Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEO

Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 Variants

Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

New 90-day high: US$3.25

Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession Committees

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Enzo Biochem Receives FDA Emergency Use Authorization for Testing Pooled Samples on Three Platforms Including company’s GENFLEX™ Proprietary System for Detection of Coronavirus SARS-Cov-2

New 90-day high: US$2.66

Enzo Biochem nabs expanded EUA nod for testing of COVID samples